ImmunityBio
IBRX
57 hedge funds and large institutions have $83.2M invested in ImmunityBio in 2017 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 24 increasing their positions, 11 reducing their positions, and 6 closing their positions.
118% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 11
118% more call options, than puts
Call options by funds: $480K | Put options by funds: $220K
0.95% more ownership
Funds ownership: 18.16% → 19.11% (+0.95%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
2% less funds holding
Funds holding: 58 → 57 (-1)
27% less capital invested
Capital invested by funds: $113M → $83.2M (-$30.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$765K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$677K |
| 3 |
Renaissance Technologies
New York
|
+$614K |
| 4 |
HK
Horizon Kinetics
New York
|
+$430K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$331K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$792K |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$632K |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$380K |
| 4 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
-$197K |
| 5 |
MLICM
Metropolitan Life Insurance Company (MetLife)
New York
|
-$180K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
BNP Paribas Financial Markets
Paris,
France
| $16.7K | -$1.08K | -176 | -5% |
|
|
AIP
52
Ameritas Investment Partners
Lincoln,
Nebraska
| $16K | – | – | – |
|
|
CG
53
Cutler Group
San Francisco,
California
| $13K | +$12.5K | +2,032 | +508% |
|
54
Federated Hermes
Pittsburgh,
Pennsylvania
| $9K | +$5.27K | +855 | +120% |
|
55
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| $3K | – | – | – |
|
|
MAM
56
Meeder Asset Management
Dublin,
Ohio
| $2K | – | – | – |
|
|
IP
57
Intellectus Partners
San Francisco,
California
| $1K | – | – | – |
|
|
58
Balyasny Asset Management
Chicago,
Illinois
| – | -$380K | -50,000 | Closed |
|
|
PPA
59
Parametric Portfolio Associates
Seattle,
Washington
| – | -$197K | -25,954 | Closed |
|
|
MLICM
60
Metropolitan Life Insurance Company (MetLife)
New York
| – | -$180K | -23,692 | Closed |
|
|
GAM
61
Gotham Asset Management
New York
| – | -$104K | -13,766 | Closed |
|
62
Nisa Investment Advisors
St. Louis,
Missouri
| – | -$100K | -12,700 | Closed |
|
IBRX Hedge Fund Activity: Q3 2017 in Review
57 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in ImmunityBio (IBRX) for Q3 2017, worth a combined $83.2M — down 27% from $113M a quarter earlier.
Fund positioning in IBRX was balanced in Q3 2017: 6 funds opened new positions, 6 closed out, 24 added to existing stakes and 11 trimmed.
The largest buyer was Invesco, adding an estimated $765K. The largest seller was JP Morgan Chase, cutting an estimated $792K.
- 57 institutional investors held ImmunityBio (IBRX) as of Q3 2017, down from 58 in Q2 2017.
- Funds reported $83.2M of ImmunityBio stock for Q3 2017, down 27% quarter-over-quarter.
- 6 funds opened new ImmunityBio positions in Q3 2017 and 6 closed out, a net change of 0 holders.
- The largest ImmunityBio buyer in Q3 2017 was Invesco, an estimated $765K added.
- The largest ImmunityBio seller in Q3 2017 was JP Morgan Chase, an estimated $792K sold.
Based on aggregated 13F filings for Q3 2017.